What is Leerink Partnrs’ Forecast for PRCT FY2025 Earnings?

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) – Equities research analysts at Leerink Partnrs reduced their FY2025 earnings per share (EPS) estimates for shares of PROCEPT BioRobotics in a report issued on Wednesday, November 5th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings of ($1.51) per share for the year, down from their previous estimate of ($1.50). The consensus estimate for PROCEPT BioRobotics’ current full-year earnings is ($1.75) per share. Leerink Partnrs also issued estimates for PROCEPT BioRobotics’ Q4 2025 earnings at ($0.33) EPS, FY2026 earnings at ($1.11) EPS, FY2027 earnings at ($0.81) EPS and FY2028 earnings at ($0.21) EPS.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.03. PROCEPT BioRobotics had a negative net margin of 28.20% and a negative return on equity of 21.72%. The company had revenue of $83.33 million for the quarter, compared to analyst estimates of $80.78 million. During the same quarter last year, the firm posted ($0.40) earnings per share. The company’s quarterly revenue was up 42.6% compared to the same quarter last year. PROCEPT BioRobotics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS.

A number of other equities research analysts have also recently issued reports on the stock. TD Cowen decreased their price target on shares of PROCEPT BioRobotics from $85.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday. Wells Fargo & Company cut their price objective on PROCEPT BioRobotics from $58.00 to $51.00 and set an “overweight” rating for the company in a research report on Wednesday. Wall Street Zen downgraded PROCEPT BioRobotics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Wednesday, October 8th. Finally, Truist Financial cut their price target on PROCEPT BioRobotics from $64.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, October 15th. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $63.30.

PROCEPT BioRobotics Stock Performance

NASDAQ:PRCT opened at $31.92 on Friday. The firm has a market capitalization of $1.78 billion, a PE ratio of -20.86 and a beta of 0.98. PROCEPT BioRobotics has a 1 year low of $29.78 and a 1 year high of $103.81. The company has a current ratio of 8.44, a quick ratio of 7.86 and a debt-to-equity ratio of 0.14. The firm’s fifty day simple moving average is $36.02 and its 200 day simple moving average is $47.66.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Osterweis Capital Management Inc. lifted its holdings in shares of PROCEPT BioRobotics by 98.0% during the 1st quarter. Osterweis Capital Management Inc. now owns 173,735 shares of the company’s stock worth $10,122,000 after acquiring an additional 85,990 shares during the period. Millennium Management LLC increased its stake in PROCEPT BioRobotics by 88.6% in the first quarter. Millennium Management LLC now owns 542,987 shares of the company’s stock valued at $31,634,000 after acquiring an additional 255,140 shares during the period. Blair William & Co. IL increased its stake in PROCEPT BioRobotics by 5.7% in the second quarter. Blair William & Co. IL now owns 497,205 shares of the company’s stock valued at $28,639,000 after acquiring an additional 26,919 shares during the period. Adage Capital Partners GP L.L.C. acquired a new position in PROCEPT BioRobotics in the first quarter worth about $2,913,000. Finally, Champlain Investment Partners LLC lifted its stake in PROCEPT BioRobotics by 48.0% during the first quarter. Champlain Investment Partners LLC now owns 676,196 shares of the company’s stock worth $39,395,000 after purchasing an additional 219,266 shares during the period. 89.46% of the stock is currently owned by institutional investors and hedge funds.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).